Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Absology

ABSOLOGY is a medical equipment manufacturer that develops and mass-produces in vitro diagnostic medical devices. ABS... read more Featured Products: More products

Download Mobile App





Absology Showcases Latest Advancements in Medical Diagnostics

By LabMedica International staff writers
Posted on 15 Nov 2023

Absology Co. More...

, Ltd. (Gyeonggi-do, Korea) is showcasing its POCT innovations at MEDICA 2023 that empower healthcare providers to deliver rapid, accurate diagnostic information at the patient's bedside. Absology is also highlighting its latest innovations in cardiac markers, infectious diseases, endocrine, urology, metabolism, and inflammation testing for humans and companion animals.

At MEDICA 2023, Absology is highlighting the ABSOL automated fluorescent immunoassay (FIA) analyzer. Designed for POCT near the patient testing device, it provides quantitative results based on immunoassay technology. The Absoludy cartridges utilize microfluidics lateral flow technology where the analyte of interest in the sample forms immune complexes while moving through the pathway in the cartridges. Inside ABSOL Analyzer, a built-in on/off valve system can actively control the flow of specimens to ensure reliable test results.

Absology is also highlighting its groundbreaking approach to Alzheimer's diagnosis with ABSOL HS. The cutting-edge POCT device, developed by ABSOLOGY's expert researchers, utilizes Photo oxidation-induced fluorescence amplification (PIFA) technology for unmatched sensitivity. It can detect Alzheimer's in its early stages, ensuring timely interventions and improved patient outcomes. Plus, ABSOL HS seamlessly integrates into the laboratory workflow, making disease detection hassle-free.

Related Links:
Absology Co., Ltd. 


New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Steam Sterilizer
Hi Vac II Line
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.